- Home
- BXC vs CAPR Comparison
BXC vs CAPR Comparison
Compare BXC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXC
- CAPR
- Stock Information
- Founded
- BXC 2004
- CAPR 2005
- Country
- BXC United States
- CAPR United States
- Employees
- BXC N/A
- CAPR N/A
- Industry
- BXC Wholesale Distributors
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BXC Consumer Discretionary
- CAPR Health Care
- Exchange
- BXC Nasdaq
- CAPR Nasdaq
- Market Cap
- BXC 663.8M
- CAPR 605.3M
- IPO Year
- BXC 2004
- CAPR N/A
- Fundamental
- Price
- BXC $76.61
- CAPR $11.50
- Analyst Decision
- BXC Strong Buy
- CAPR Strong Buy
- Analyst Count
- BXC 5
- CAPR 7
- Target Price
- BXC $126.20
- CAPR $39.29
- AVG Volume (30 Days)
- BXC 88.8K
- CAPR 1.6M
- Earning Date
- BXC 04-29-2025
- CAPR 03-19-2025
- Dividend Yield
- BXC N/A
- CAPR N/A
- EPS Growth
- BXC 14.84
- CAPR N/A
- EPS
- BXC 6.19
- CAPR N/A
- Revenue
- BXC $2,952,532,000.00
- CAPR $22,270,465.00
- Revenue This Year
- BXC $4.52
- CAPR $34.33
- Revenue Next Year
- BXC $5.77
- CAPR $246.72
- P/E Ratio
- BXC $12.38
- CAPR N/A
- Revenue Growth
- BXC N/A
- CAPR N/A
- 52 Week Low
- BXC $73.01
- CAPR $3.52
- 52 Week High
- BXC $134.79
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- BXC 36.10
- CAPR 40.48
- Support Level
- BXC $79.74
- CAPR $12.64
- Resistance Level
- BXC $84.33
- CAPR $13.81
- Average True Range (ATR)
- BXC 2.68
- CAPR 1.14
- MACD
- BXC 0.76
- CAPR -0.07
- Stochastic Oscillator
- BXC 9.81
- CAPR 12.38
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.